VIRBAC: insider trades · France · AMF

About VIRBAC

Virbac is a global animal health company focused on the development, manufacturing and commercialization of solutions for veterinarians, farmers and pet owners. The group offers a broad and practical portfolio spanning companion animals and farm animals, with products and services that address key therapeutic and preventive needs. Its ranges include antiparasitics, dermatology treatments, oral health products, mobility solutions, reproduction-related products, specialty nutrition, and preventive and therapeutic solutions for ruminants and other livestock. Virbac operates in more than 100 countries and maintains manufacturing sites and R&D centers across five continents, giving it a substantial international industrial and commercial footprint. Virbac was founded in 1968 by veterinarian Pierre-Richard Dick in Carros, near Nice, France, with the ambition of creating medicines specifically designed for animal health. Over time, the company expanded through a combination of internal innovation and targeted acquisitions, while remaining centered on veterinary medicine. This long-term strategy helped Virbac build a strong reputation among animal health professionals, especially through differentiated products and a close relationship with veterinarians. The company also emphasizes a sustained innovation culture, supported by regular R&D investment and the launch of solutions aimed at unmet or under-served medical needs. Strategically, Virbac stands out for its balanced mix of specialty products and broader core ranges, as well as for its diversified geographic exposure. Europe remains a key region, but the group also holds meaningful positions in North America, Asia-Pacific, Latin America, India and the Middle East/Africa. Full-year 2025 results showed solid commercial momentum, with revenue reaching €1.465 billion, up 4.8% on a reported basis and 7.9% at constant exchange rates and scope. Growth was supported by companion-animal momentum, specialty launches and targeted acquisitions such as Sasaeah in Japan and Mopsan in Türkiye. Virbac also announced that Paul Martingell would become CEO effective September 1, 2025, marking a new phase in the company’s international development.